A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Official title

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Study identification

NCT ID

NCT04546399

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 2

Lead sponsor

National Cancer Institute (NCI)

NIH

Enrollment

461 participants

Conditions and interventions

Eligibility (public fields only)

Age range

1 Year to 30 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Dec 16, 2020

Primary completion

Jun 29, 2028

Completion

Jun 29, 2028

Last update posted

Sep 9, 2025

2020 – 2028

United States locations

U.S. sites

202

U.S. states

47

U.S. cities

146

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.